Concord Biotech Limited (NSE: CONCORDBIO)
India
· Delayed Price · Currency is INR 2,019.30
+28.10 (1.41%)
Nov 22, 2024, 3:30 PM IST
Concord Biotech Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
| Net Income | 3,279 | 3,081 | 2,401 | 1,749 | 2,349 | 1,691 |
| Depreciation & Amortization | 536.99 | 535.43 | 538.94 | 498.96 | 273.69 | 210.88 |
| Other Amortization | 0.49 | 0.49 | 1.39 | 1.55 | 1.54 | 1.57 |
| Loss (Gain) From Sale of Assets | -0.11 | -0.12 | 0.94 | 0.34 | - | -0.52 |
| Loss (Gain) From Sale of Investments | -186.83 | -140.65 | -37.17 | -52.3 | -69.86 | -124.16 |
| Loss (Gain) on Equity Investments | 7.82 | -33.71 | -19.59 | 36.38 | 4.49 | -1.5 |
| Provision & Write-off of Bad Debts | 15.43 | 6.69 | 0.92 | -3.46 | 4.59 | 5.16 |
| Other Operating Activities | -119.38 | 17.31 | 96.59 | 71.19 | -7.52 | -16.87 |
| Change in Accounts Receivable | -804.66 | -786.6 | -430.97 | -527.69 | 65.01 | -294.31 |
| Change in Inventory | -305.67 | 43.61 | -172.27 | -415.12 | -423.77 | -195.14 |
| Change in Accounts Payable | 181.17 | -112.87 | 98.81 | 365.35 | -225.1 | 392.65 |
| Change in Other Net Operating Assets | 390.11 | 44.06 | -18.42 | 356.91 | -303.77 | -120.44 |
| Operating Cash Flow | 2,995 | 2,655 | 2,460 | 2,081 | 1,668 | 1,548 |
| Operating Cash Flow Growth | 12.38% | 7.91% | 18.19% | 24.77% | 7.73% | - |
| Capital Expenditures | -1,056 | -856.89 | -1,451 | -1,555 | -2,042 | -1,555 |
| Sale of Property, Plant & Equipment | 1.4 | 1.75 | 0.25 | 0.56 | - | 1.7 |
| Investment in Securities | -838.57 | -718.69 | -184.76 | 395.22 | 88.64 | 425.13 |
| Other Investing Activities | 37.19 | 27.73 | 55.85 | 41.4 | 1.07 | 0.05 |
| Investing Cash Flow | -1,856 | -1,546 | -1,580 | -1,118 | -1,952 | -1,128 |
| Short-Term Debt Issued | - | - | - | - | 50.99 | - |
| Long-Term Debt Issued | - | - | - | - | 519.72 | 480.28 |
| Total Debt Issued | - | - | - | - | 570.71 | 480.28 |
| Short-Term Debt Repaid | - | - | -43.37 | - | - | - |
| Long-Term Debt Repaid | - | -265.04 | -265.96 | -266.56 | -202.41 | -106.08 |
| Total Debt Repaid | -203.33 | -265.04 | -309.33 | -266.56 | -202.41 | -106.08 |
| Net Debt Issued (Repaid) | -203.33 | -265.04 | -309.33 | -266.56 | 368.3 | 374.2 |
| Common Dividends Paid | -915.39 | -714.53 | -535.64 | -705.21 | -57.06 | -805.45 |
| Other Financing Activities | -6.86 | -12.58 | -7.23 | -22.26 | - | -2.91 |
| Financing Cash Flow | -1,126 | -992.15 | -852.19 | -994.02 | 311.24 | -434.16 |
| Miscellaneous Cash Flow Adjustments | - | - | - | -14.29 | - | - |
| Net Cash Flow | 13.22 | 116.43 | 28.32 | -44.77 | 27.36 | -13.51 |
| Free Cash Flow | 1,939 | 1,798 | 1,009 | 526.36 | -373.59 | -6.23 |
| Free Cash Flow Growth | 22.01% | 78.15% | 91.73% | - | - | - |
| Free Cash Flow Margin | 17.86% | 17.68% | 11.83% | 7.38% | -6.06% | -0.12% |
| Free Cash Flow Per Share | 18.54 | 17.18 | 9.65 | 5.03 | -3.57 | -0.06 |
| Cash Interest Paid | 14.28 | 26.5 | 39.58 | 53.15 | - | 2.91 |
| Cash Income Tax Paid | 1,295 | 1,033 | 702.77 | 607.85 | 751.77 | 491.16 |
| Levered Free Cash Flow | 780.35 | 1,178 | 505.95 | 188.91 | -831.9 | - |
| Unlevered Free Cash Flow | 788.44 | 1,194 | 534.14 | 223.18 | -827.74 | - |
| Change in Net Working Capital | 1,276 | 902.67 | 429.5 | 153.68 | 951.1 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.